LONDON–(EMWNews)–The demand for novel drug delivery systems is rising and pharmaceutical

companies have been involved in developing innovative new methods.

Impending patent expirations will stimulate a surge in novel drug

delivery methods for existing products, while sophisticated

reformulation will generate substantial revenues in the European

pharmaceutical market.

New analysis from Frost & Sullivan (http://www.pharma.frost.com),

European Drug Delivery Market-Opportunity Analysis, finds that

the European pulmonary drug delivery market earned revenues of USD 7.00

billion in 2007 and estimates this to reach USD 12.94 billion in 2014.

The analysis also finds that the European transdermal drug delivery

market earned revenues of USD 4.04 billion in 2007 and estimates this to

reach USD 7.87 billion in 2014.

“Drug delivery is a fast growing and highly

dynamic segment of the pharmaceutical and biotechnology industry,”

notes Frost & Sullivan Industry Analyst Sylvia Miriyam

Findlay. “Various factors have contributed to

the growth of this area, including the poor efficacies of certain drugs,

patent expirations and the urgent need for life cycle management facing

drugs nearing patent expiry.”

However, pharmaceutical companies are looking to enhance the safety

record of their products by introducing novel drug delivery

technologies. This will also boost their competitive edge and enable

them to maximise revenue generation.

The foremost challenge presented by the pulmonary route of drug delivery

is the inability to deliver drugs directly to the alveoli. In addition,

large molecules do not permeate the skin barrier and hence, fail to be

delivered by the transdermal method. Ineffective drug delivery presents

a significant technological challenge to market expansion.

“Market participants should focus on

developing novel technologies that support the passage of large peptides,”

notes Findlay. “This will be critical to

sustaining market growth, as the pharmaceutical/biotechnology industry

is moving towards monoclonal antibody (Mab) therapeutics. Mabs, which

are large peptides, are already being used in various therapeutic

applications.”

If you are interested in a virtual brochure, which provides

manufacturers, end users and other industry participants with an

overview of the European drug delivery market-opportunity analysis, then

send an e-mail to Patrick Cairns, Corporate Communications, at pcairns_[email protected],

with your full name, company name, title, telephone number, company

e-mail address, company website, city, state and country. Upon receipt

of the above information, an overview will be sent to you by e-mail.

European Drug Delivery Market-Opportunity Analysis is part of the Pharmaceutical

and Clinical Diagnostics Growth Partnership Service Programme, which

also includes research in the following markets: European Fibromyalgia

Market and European Growth Hormone Market. All research included in

subscriptions provide detailed market opportunities and industry trends

that have been evaluated following extensive interviews with market

participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners

with clients to accelerate their growth. The company’s TEAM Research,

Growth Consulting and Growth Team Membership™

empower clients to create a growth-focused culture that generates,

evaluates and implements effective growth strategies. Frost & Sullivan

employs over 45 years of experience in partnering with Global 1000

companies, emerging businesses and the investment community from more

than 30 offices on six continents. For more information about Frost &

Sullivan’s Growth Partnerships, visit http://www.frost.com.

European Drug Delivery Market –

Opportunity Analysis

M214

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions